Beginning around the 36th week of pregnancy a weekly acupuncture treatment can really help first-time moms. With acupuncture support they have a better chance of avoiding a long, drawn-out labor. A midwife in New Zealand in the early 2000s kept track of how women having their first baby responded to acupuncture. Over a 4-month period she found the moms who’d had 3 pre-birth acupuncture treatments, coming in once a week, spent less time in active labor. With acupuncture support labor lasted 5 hrs, 9 hrs, 7 hrs, 7 hrs, 6 hrs and 7 hrs. Without pre-birth acupuncture the average labor was 14 hrs. That’s quite a difference. In an observational study in 2004 of 169 women who’d received prebirth acupuncture compared to local population rates, acupuncturist Debra Betts and midwife Sue Lennox found that with acupuncture there were 35% fewer inductions and a 31% reduction in epidurals. For first babies it was even better with 43% fewer inductions. In the group of babies delivered by midwives there were 32% fewer emergency c-sections and a 9 % increase in normal vaginal births. With weekly acupuncture treatments labor typically progresses well without stopping and starting, usually beginning before 42 weeks. If a medical induction is necessary it often goes more smoothly for people who’ve had regular weekly acupuncture sessions to help their body prepare for labor. Some points support cervical ripening or release tension in the hips and pelvis. Others can help the baby move into a good position, ready for birth. At anytime in pregnancy acupuncture can address discomforts like heartburn, insomnia, anxiety, back pain, swollen hands & feet, nasal congestion and constipation. Plus it’s also a good support for the western treatment of pregnancy-induced hypertension or gestational diabetes, coordinating care with your obstetrician or midwife. So, to increase your chances of a natural, efficient labor consider adding acupuncture support near the end of your pregnancy. Look for an experienced acupuncturist who specializes in pregnancy care like the ones who practice at A Woman’s Time. Janene Mitchell, LAc,...
Comparing the Risk of DVT Between Two Popular Birth Control Pills: Norethindrone vs. Drospirenone
By Danielle Melvin, N.D. Combined oral contraceptives (COCs) have been a cornerstone of birth control for decades, offering women effective options for pregnancy prevention, hormonal regulation, and symptom management related to conditions like acne and menstrual irregularities. However, one concern that has long accompanied the use of COCs is the potential risk of deep vein thrombosis (DVT)—a serious condition where blood clots form in deep veins, often in the legs, which can lead to life-threatening complications like pulmonary embolism. Norethindrone vs. Drospirenone: How Do They Compare? Norethindrone is a first-generation progestin with a long history of use. It is generally well-tolerated and has been associated with a lower risk of side effects, including thrombotic events. Drospirenone, on the other hand, is a newer, fourth-generation progestin. It has gained popularity because of its anti-androgenic effects, making it beneficial for women with acne or hormonal imbalances. However, previous studies have suggested that drospirenone might carry a higher risk of DVT compared to earlier-generation progestins like norethindrone. Study Findings: Who’s at Higher Risk? Higher DVT Risk with Drospirenone: The study confirmed that women who used drospirenone/ethinyl estradiol had a higher incidence of DVT compared to those using norethindrone/ethinyl estradiol. This aligns with previous research that has raised concerns about the thrombotic risks associated with drospirenone. Overall Risk Still Low: While the risk was higher with drospirenone, it’s important to emphasize that the overall risk of developing DVT for healthy women using COCs remains low. For most women, the benefits of contraception, such as preventing unintended pregnancies and managing menstrual symptoms, far outweigh the risks. Other Risk Factors Matter: The study also reinforced the idea that other individual risk factors—such as being overweight, smoking, or having a personal or family history of blood clots—play a significant role in determining DVT risk. Women with these risk factors should carefully discuss contraceptive options with their healthcare provider Key Takeaways for Choosing a COC: Know Your Risk Factors: Before starting any contraceptive, it’s crucial to assess your personal risk factors for DVT. If you have a family history of blood clots, are a smoker, or have other medical conditions that increase your risk, this should factor into your choice of contraception. Discuss Options with Your Clinician: Healthcare providers can help guide you through the pros and cons of different contraceptives based on your health history. They can recommend the best option based on your individual risk profile. Consider Non-Hormonal Alternatives: If you’re at high risk for DVT but still need effective birth control, non-hormonal options like the copper IUD or barrier methods may be worth considering. These options do not carry the same clotting risks as estrogen-containing contraceptives. Weigh the Benefits and Risks: For many women,...
The Berry Benefits: Insights from NHANES on Flavonoids and Mortality
By Danielle Melvin, N.D. In recent years, the health benefits of fruits and vegetables have been spotlighted, and among them, berries have emerged as a nutritional superstar. Data from the National Health and Nutrition Examination Survey (NHANES) highlights the role of berries and flavonoids in improving overall health and extending longevity, based on dietary intake and lifestyle factors from 1999 to 2014. Key Findings on Berries and Flavonoids Flavonoid Power: Berries are rich in flavonoids, a group of antioxidants known for their anti-inflammatory properties. The study found a significant correlation between higher consumption of flavonoid-rich foods, particularly berries, and reduced mortality rates. This suggests that incorporating more berries into our diets could have protective effects against chronic diseases. Longevity Benefits: Participants who consumed higher amounts of berries showed lower rates of death from all causes compared to those who consumed fewer or no berries. The evidence indicates that regular consumption could contribute to a longer, healthier life. Diverse Berry Varieties: The study examined various types of berries—strawberries, blueberries, blackberries, and raspberries—each demonstrating unique benefits. This diversity underscores the importance of a varied diet rich in different fruits to maximize health benefits. How Berries Work Their Magic The antioxidants in berries, particularly flavonoids, combat oxidative stress and inflammation in the body. This mechanism helps lower the risk of chronic diseases such as heart disease, diabetes, and certain cancers. Furthermore, the fiber in berries supports digestive health and can aid in weight management, contributing to overall well-being. Practical Tips for Incorporating More Berries Start Your Day Right: Add a handful of berries to your morning oatmeal or yogurt for a flavorful and nutritious boost. Snack Smart: Keep fresh berries on hand for a quick, healthy snack instead of processed options. They’re not only delicious but also filling. Blend It Up: Throw berries into smoothies for a refreshing treat that packs a nutrient punch. Bake with Berries: Incorporate them into muffins, pancakes, or desserts to add natural sweetness and nutrition. Freeze for Later: Buy in bulk when berries are in season and freeze them for later use. This way, you can enjoy their health benefits year-round. Conclusion: Berry Up for Better Health The findings from the NHANES study provide compelling evidence that consuming berries and other flavonoid-rich foods can contribute to a longer, healthier life. As we continue to learn more about the connections between diet and health, it’s clear that small changes—like adding more berries to our meals—can have a profound impact. So next time you’re at the grocery store, don’t forget to stock up on these delicious, nutrient-packed fruits. Your body (and your taste buds) will thank you! Danielle Melvin, N.D. is available for nutritional consultations in addition to all...
Low libido in Women: Understanding New Medications and Alternative Options
Low sexual desire in women has been a complex and understudied issue, often overshadowed by its male counterpart. Low sexual desire in women is a multifaceted issue with various contributing factors, including psychological, hormonal, and relational elements. Historically, addressing this concern has been challenging, and the approval of medications specifically targeting female sexual dysfunction has been met with both anticipation and skepticism. Currently on the market is two FDA approved medications for women to combat low sexual desire. Bremelanotide, often dubbed the “female Viagra,” and Flibanserin, marketed as a treatment for hypoactive sexual desire disorder (HSDD), have both received regulatory approval. However, the approval processes for these drugs raise critical questions about the fallacy of regulatory precedent in addressing women’s sexual health. Bremelanotide, an injectable medication, has faced scrutiny for its potential side effects, including nausea and vomiting. While it has been approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), concerns linger about the long-term safety and efficacy of this treatment. Flibanserin, approved as a daily pill for premenopausal women with HSDD, has been on the market for a few years. However, its approval process was not without controversy, with initial rejections citing marginal efficacy and significant side effects. The ongoing debate questions whether the regulatory approval truly aligns with the needs of women seeking solutions for low sexual desire. The approval of Bremelanotide and Flibanserin raises broader questions about the regulatory framework for women’s sexual health medications. Critics argue that the bar for approval may be lower than for male counterparts, potentially leading to the availability of drugs with questionable efficacy and safety profiles. While the approval of Bremelanotide and Flibanserin signifies progress in acknowledging and addressing low sexual desire in women, it also prompts a reevaluation of regulatory standards. As discussions surrounding women’s sexual health gain momentum, it becomes imperative to scrutinize the fallacy of regulatory precedent and ensure that approved medications genuinely meet the diverse needs of women, both in terms of efficacy and safety. As we navigate this evolving landscape, critical dialogue and continued research will play a pivotal role in shaping the future of treatments for low sexual desire in women. While these medications may be one solution to improving sexual desire, there are several other options to consider. Topical testosterone therapy is a promising option practitioners can prescribe for both pre and postmenopausal women. There are also numerous herbs backed by research studies such as Maca, Fenugreek, Tribulus, and Ashwagandha that may also provide improvement. Ultimately, it falls upon the practitioner to provide all available treatment options and collaborate with the patient to determine the most suitable approach to address their specific needs. Article by Danielle Melvin, N.D. Source:...
Benefits of N-Acetylcysteine in Managing Endometriosis
Endometriosis is defined as a chronic, multi-mechanistic and estrogen-dependent, inflammatory disease, that is often debilitating to many women worldwide. This condition occurs when tissue similar to the lining of the uterus grows outside the womb, leading to pain, inflammation, and the formation of cysts. Conventional treatments include surgery, pain medication, and hormonal therapies, however, emerging research suggests that N-acetylcysteine (NAC) might offer additional benefits. NAC, known for its antioxidant and anti-proliferative effects on tissue, has been shown in previous studies to alleviate pelvic pain and reduce the size of endometriomas (cysts on the ovaries due to endometriosis). Emerging research is also theorizing that NAC may also reduce Cancer Antigen 125 (Ca125) production and help improve fertility. The focus of this study was to confirm the effectiveness of NAC in reducing endometriosis related pain, improve fertility, and reduce Ca125 serum levels. Patients were given 600mg of oral NAC, 3 tablets/day for 3 consecutive days of the week for 3 months. After 3 months, the intensity of menstrual cramps, pain with vaginal penetration during sex and chronic pelvic pain were evaluated along with evaluation of endometrioma size via transvaginal ultrasound. Serum Ca125 levels were determined as well as fertility outcomes. 120 patients ages between 18 and 45 years old with clinical/ instrumental or surgical/ histological diagnosis of endometriosis were recruited for this study. Exclusion criteria included 1) pre-menarche and menopausal 2) known hypersensitivity to NAC 3) current hormone treatment, cancer diagnosis, or pregnancy. Results showed significant improvement in the intensity of dysmenorrhea, dyspareunia, and chronic pelvic pain, decrease in serum Ca125 levels, and decrease in the size of endometriomas among the patients. Out of a total of 52 patients with reproductive desires, 39 successfully achieved pregnancy within 6 months of starting NAC treatment. Overall, NAC is a promising natural therapy to help patients struggling with endometriosis manage their pain, improve quality of life, and enhance fertility outcomes. NAC is usually used in combination with other natural therapies that target additional mechanisms involved in endometriosis. These include resveratrol, melatonin, pine bark extract, green tea, and curcumin. Individual treatment plans are based on the specific pelvic symptoms, health history and other medical conditions that the patient is experiencing. Article by Danielle Melvin, N.D. Source: Anastasi E, Scaramuzzino S, Viscardi MF, Viggiani V, Piccioni MG, Cacciamani L, Merlino L, Angeloni A, Muzii L, Porpora MG. Efficacy of N-Acetylcysteine on Endometriosis-Related Pain, Size Reduction of Ovarian Endometriomas, and Fertility Outcomes. Int J Environ Res Public Health. 2023 Mar 7;20(6):4686. doi: 10.3390/ijerph20064686. PMID: 36981595; PMCID:...